Arbutus Biopharma Total Revenue

Arbutus Biopharma (ABUS) currently reports a total revenue of $180M as of June 2026. That compares with $15M in the prior-year period — up 1078.8% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Arbutus Biopharma's total revenue history and peer comparisons.

Arbutus Biopharma's total revenue increased from $15M to $180M — a 1078.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Arbutus Biopharma's total revenue of $180M is lower than the Healthcare sector average of $110B. That is roughly 99.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Arbutus Biopharma reported $180M in total revenue as of June 2026. That compares with $15M in the prior-year period — up 1078.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $180M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Arbutus Biopharma, and consider following ABUS for alerts when major investors trade the stock.